ℹ️
🇬🇧
Search
Search for publications relevant for "MRI outcomes"
MRI outcomes
Publication
Class
Person
Publication
Programmes
publication
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS
2007 |
First Faculty of Medicine
publication
Long‑term effect of siponimod on MRI outcomes in patients with secondary‑progressive multiple sclerosis
2022 |
Faculty of Medicine in Hradec Králové
publication
Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon beta-1a in MS
2016 |
First Faculty of Medicine
publication
Multiple sclerosis susceptibility loci do not alter clinical and MRI outcomes in clinically isolated syndrome
2013 |
First Faculty of Medicine
publication
Altered Cytokine Endotoxin Responses in Neonatal Encephalopathy Predict MRI Outcomes
2021 |
Central Library of Charles University
publication
ApoE epsilon 4 positivity does not predict more severe clinical and MRI outcome: a 5-year longitudinal study
Publication without faculty affiliation
publication
Long-term effectiveness of natalizumab on MRI outcomes and no evidence of disease activity in relapsing-remitting multiple sclerosis patients treated in a Czech Republic real-world setting: A longitudinal, retrospective study
2020 |
First Faculty of Medicine
publication
The relation of radiological tumor volume response to histological response and outcome in patients with localized Ewing Sarcoma
2019 |
Second Faculty of Medicine
publication
Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis
2021 |
First Faculty of Medicine
publication
Understanding the positive benefit: risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
2017 |
First Faculty of Medicine, Second Faculty of Medicine
publication
The role of cholesterol metabolism in multiple sclerosis: From molecular pathophysiology to radiological and clinical disease activity
2022 |
First Faculty of Medicine
publication
Bimonthly Evolution of Cortical Atrophy in Early Relapsing-Remitting Multiple Sclerosis over 2 Years : A Longitudinal Study
2013 |
First Faculty of Medicine
publication
Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review
2017 |
First Faculty of Medicine
publication
Serum lipid profile changes predict neurodegeneration in interferon-beta 1a-treated multiple sclerosis patients
2017 |
First Faculty of Medicine
publication
Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis
2017 |
First Faculty of Medicine
publication
Assessment of T2 lesion-based disease activity volume outcomes in predicting disease progression in multiple sclerosis over 10 years
2022 |
First Faculty of Medicine
publication
Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results From Randomized Phase 2b Core and Extension Studies
2022 |
First Faculty of Medicine